Fibromyalgia Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, Tonix Pharma

DelveInsight’s “Fibromyalgia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Fibromyalgia, historical and forecasted epidemiology as well as the Fibromyalgia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Fibromyalgia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fibromyalgia Market Forecast

Some of the key facts of the Fibromyalgia Market Report: 

• The Fibromyalgia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• According to Queiroz’s Worldwide Epidemiology of Fibromyalgia, the average prevalence of fibromyalgia was 2.7% worldwide, 3.1% in America, 2.5% in Europe, and 1.7% in Asia
• According to Dan Buskila et al., FM is more common in women (3.4%) than in men (0.5%) in the general population of the United States, where the frequency is estimated to be 2%
• According to a study by Neumann et al., the prevalence of fibromyalgia was shown to range from 0.5% to 5% in the general population and to reach 15.7% in clinics
• Key Fibromyalgia Companies: Tonix Pharmaceutical, UCB Biopharma SRL, GlaxoSmithKline, UCB Pharma, Pierre Fabre Medicament, UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, AstraZeneca, RiboCor, Inc., Bial – Portela C S.A, and others
• Key Fibromyalgia Therapies: TNX102 SL, Rozanolixizumab, Paroxetine CR, Lacosamide, milnacipran, Rotigotine, Duloxetine, Saizen®, NYX-2925, ASP8062, Quetiapine, D-Ribose Powder, ESL 400, and others
• The Fibromyalgia epidemiology based on gender analyzed that, FM disease affects females more as compared to males. According to Queiroz, the mean prevalence of FM was 4.2% in female and 1.4 % in men, with a female to-male ratio of 3:1
• The Fibromyalgia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fibromyalgia pipeline products will significantly revolutionize the Fibromyalgia market dynamics.

Fibromyalgia Overview

Fibromyalgia, also known as fibromyalgia syndrome, is a common and complex chronic pain condition that affects people’s mental, physical, and social well-being and produces musculoskeletal discomfort, tiredness, and localised soreness. Although the precise origin is uncertain, genetic problems are the main contributors.

Get a Free sample for the Fibromyalgia Market Report 

https://www.delveinsight.com/report-store/fibromyalgia-market

Fibromyalgia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Fibromyalgia Epidemiology Segmentation:

The Fibromyalgia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Fibromyalgia
• Prevalent Cases of Fibromyalgia by severity
• Gender-specific Prevalence of Fibromyalgia
• Diagnosed Cases of Episodic and Chronic Fibromyalgia

Download the report to understand which factors are driving Fibromyalgia epidemiology trends @ Fibromyalgia Epidemiology Forecast

Fibromyalgia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fibromyalgia market or expected to get launched during the study period. The analysis covers Fibromyalgia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Fibromyalgia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Fibromyalgia Therapies and Key Companies

• TNX102 SL: Tonix Pharmaceutical
• Rozanolixizumab: UCB Biopharma SRL
• Paroxetine CR: GlaxoSmithKline
• Lacosamide: UCB Pharma
• milnacipran: Pierre Fabre Medicament
• Rotigotine: UCB Pharma
• Duloxetine: Eli Lilly and Company
• Saizen®: Merck
• TNX-102 SL: Tonix Pharmaceuticals, Inc.
• NYX-2925: Aptinyx
• ASP8062: Astellas Pharma
• Quetiapine: AstraZeneca
• D-Ribose Powder: RiboCor, Inc.
• ESL 400: Bial – Portela C S.A

Discover more about therapies set to grab major Fibromyalgia market share @ Fibromyalgia Treatment Market

Scope of the Fibromyalgia Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Fibromyalgia Companies: Tonix Pharmaceutical, UCB Biopharma SRL, GlaxoSmithKline, UCB Pharma, Pierre Fabre Medicament, UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, AstraZeneca, RiboCor, Inc., Bial – Portela C S.A, and others
• Key Fibromyalgia Therapies: TNX102 SL, Rozanolixizumab, Paroxetine CR, Lacosamide, milnacipran, Rotigotine, Duloxetine, Saizen®, NYX-2925, ASP8062, Quetiapine, D-Ribose Powder, ESL 400, and others
• Fibromyalgia Therapeutic Assessment: Fibromyalgia current marketed and Fibromyalgia emerging therapies
• Fibromyalgia Market Dynamics: Fibromyalgia market drivers and Fibromyalgia market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Fibromyalgia Unmet Needs, KOL’s views, Analyst’s views, Fibromyalgia Market Access and Reimbursement 

To know more about Fibromyalgia companies working in the treatment market, visit @ Fibromyalgia Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Fibromyalgia Market Report Introduction

2. Executive Summary for Fibromyalgia

3. SWOT analysis of Fibromyalgia

4. Fibromyalgia Patient Share (%) Overview at a Glance

5. Fibromyalgia Market Overview at a Glance

6. Fibromyalgia Disease Background and Overview

7. Fibromyalgia Epidemiology and Patient Population

8. Country-Specific Patient Population of Fibromyalgia 

9. Fibromyalgia Current Treatment and Medical Practices

10. Fibromyalgia Unmet Needs

11. Fibromyalgia Emerging Therapies

12. Fibromyalgia Market Outlook

13. Country-Wise Fibromyalgia Market Analysis (2019–2032)

14. Fibromyalgia Market Access and Reimbursement of Therapies

15. Fibromyalgia Market Drivers

16. Fibromyalgia Market Barriers

17.  Fibromyalgia Appendix

18. Fibromyalgia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/